Indaptus Therapeutics Stock (NASDAQ:INDP)


RevenueOwnershipFinancialsChart

Previous Close

$1.03

52W Range

$1.03 - $3.10

50D Avg

$1.30

200D Avg

$1.91

Market Cap

$10.81M

Avg Vol (3M)

$111.75K

Beta

1.13

Div Yield

-

INDP Company Profile


Indaptus Therapeutics, Inc., a pre-clinical biotechnology company, develops various anti-cancer and anti-viral immunotherapy products. Its lead clinical oncology candidate is Decoy20 to single agent activity and/or combination therapy-based durable responses of lymphoma, hepatocellular, colorectal, and pancreatic tumors, as well as hepatitis B virus and human immunodeficiency virus infection, which is in Phase I clinical trial. The company was formerly known as Intec Parent, Inc. and changed its name to Indaptus Therapeutics, Inc. in August 2021. Indaptus Therapeutics, Inc. was incorporated in 2021 and is headquartered in New York, New York.

Show More

Industry

Biotechnology

Sector

Healthcare

Exchange

NASDAQ

ADR

-

Country

US

Employees

7

IPO Date

Aug 04, 2015

Website

INDP Performance


INDP Financial Summary


Dec 23Dec 22Dec 21
Revenue---
Operating Income$-16.38M$-14.91M$-7.73M
Net Income$-15.42M$-13.73M$-7.69M
EBITDA$-16.38M$-14.91M$-7.73M
Basic EPS$-1.84$-1.66$-1.88
Diluted EPS$-1.84$-1.66$-1.88

Fiscal year ends in Dec 23 | Currency in USD

Peer Comparison


TickerCompany
NTRBNutriband Inc.
MTCRMetacrine, Inc.
BWVOnconetix, Inc.
ABVCABVC BioPharma, Inc.
KPRXKiora Pharmaceuticals, Inc.
KTTAPasithea Therapeutics Corp.
LGVNLongeveron Inc.
REVBRevelation Biosciences, Inc.
QNRXQuoin Pharmaceuticals, Ltd.
HILSTharimmune, Inc.
VRAXVirax Biolabs Group Limited
ASMBAssembly Biosciences, Inc.
RNXTRenovoRx, Inc.
RZLTRezolute, Inc.
TPSTTempest Therapeutics, Inc.
ANEBAnebulo Pharmaceuticals, Inc.
FBRXForte Biosciences, Inc.